on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress
On June 20, 2024, the company OSE Immunotherapeutics unveiled encouraging preclinical results on its therapeutic mRNA platform at the FOCIS congress in San Francisco. Data show that mRNA therapeutic targeting Interleukin-35 (IL-35), used via lipid nanoparticles, effectively reduces hepatic autoimmune inflammation.
IL-35 is an immunosuppressive cytokine modulating several immune cells to limit inflammation. Preclinical studies have demonstrated that it plays a crucial role in the control of autoimmune and inflammatory diseases, including autoimmune hepatitis.
Aurore Morello, Director of R&D at OSE Immunotherapeutics, expressed satisfaction with the initial results, highlighting the potential of this new approach to address an important medical need in autoimmune and inflammatory diseases.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news